Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Masked biologics technology enables targeting of challenging cancer antigens, with lead ADC showing strong efficacy and manageable GI toxicity in late-line CRC. Dose optimization and registrational plans are underway, with expansion into other GI cancers and a masked cytokine program in melanoma.Ba…
CTMX’s lead EpCAM-targeting ADC reported robust efficacy in late-line colorectal cancer at a conference, alongside manageable safety and a clear regulatory path. The company also highlighted expansion into combinations and other GI tumors.